{"nctId":"NCT00465088","briefTitle":"An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)","startDateStruct":{"date":"2007-04"},"conditions":["Hyperlipidemia","Mixed Dyslipidemia"],"count":199,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Niacin ER/Simvastatin Tablets"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: atorvastatin"]}],"interventions":[{"name":"Niacin ER/Simvastatin Tablets","otherNames":["ABT-919/483","Niacin ER/Simvastatin","Simcor"]},{"name":"atorvastatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must meet all of the following laboratory criteria:\n\n  * HDL-C \\<40 mg/dL for men and \\<50 mg/dL for women.\n  * LDL-C â‰¥130 mg/dL but \\<250 mg/dL.\n  * TG \\<350 mg/dL.\n  * Creatine phosphokinase (CPK) \\< 3 x upper limit of normal (ULN).\n  * Alanine aminotransferase (ALT); serum glutamic pyruvic transaminase \\[SGPT\\] and aspartate aminotransferase (AST); serum glutamic oxaloacetic transaminase \\[SGOT\\] \\< 1.3 x ULN.\n* Subjects must also be reasonably compliant with the Therapeutic Lifestyle Changes (TLC) diet during the 4 to 5 week Screening Period prior to randomization (and be willing to comply for the duration of the study).\n\nExclusion Criteria:\n\n* Subjects who have a history of any important medical conditions or abnormalities (as specified in the protocol) that would preclude study inclusion","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12","description":"(Week 12 HDL-C minus baseline HDL-C) x 100/baseline HDL-C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in HDL-C From Baseline to Week 8","description":"(Week 8 HDL-C minus baseline HDL-C) x 100/baseline HDL-C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-HDL-C From Baseline to Week 8","description":"(Week 8 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.0","spread":null},{"groupId":"OG001","value":"-44.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-HDL-C From Baseline to Week 12","description":"(Week 12 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.4","spread":null},{"groupId":"OG001","value":"-43.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12","description":"(Week 12 LDL-C minus baseline LDL-C) x 100/baseline LDL-C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.8","spread":null},{"groupId":"OG001","value":"-46.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides From Baseline to Week 12","description":"(Week 12 triglycerides minus baseline triglycerides) x 100/baseline triglycerides","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.0","spread":null},{"groupId":"OG001","value":"-37.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in LDL-C:HDL-C Ratio","description":"(Week 12 LDL-C:HDL-C ratio minus baseline LDL-C:HDL-C ratio) x 100/baseline LDL-C:HDL-C ratio","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.5","spread":null},{"groupId":"OG001","value":"-50.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Cholesterol From Baseline to Week 12","description":"(Week 12 total cholesterol minus baseline total cholesterol) x 100/baseline total cholesterol","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.3","spread":null},{"groupId":"OG001","value":"-35.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Cholesterol:HDL-C Ratio","description":"(Week 12 total cholesterol:HDL-C ratio minus baseline total cholesterol:HDL-C ratio) x 100/baseline total cholesterol:HDL-C ratio","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.2","spread":null},{"groupId":"OG001","value":"-40.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Lipoprotein A From Baseline to Week 12","description":"(Week 12 lipoprotein A minus baseline lipoprotein A) x 100/baseline lipoprotein A","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.8","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Meeting With HDL-C >/= 40 mg/dL at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12","description":"For high-risk patients (coronary heart disease or equivalent), LDL-C \\< 100 mg/dL and non-HDL-C \\< 130 mg/dL; for moderate risk patients (having 2 risk factors), LDL-C \\< 130 mg/dL and non-HDL-C \\< 160 mg/dL; for low-risk patients (having 0 or 1 risk factor): LDL-C \\< 160 mg/dL and non-HDL-C \\< 190 mg/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Triglycerides < 150 mg/dL at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With HDL-C >/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides < 150 mg/dL at Week 12","description":"NCEP ATP III goals for LDL-C are as follows: For high-risk patients, LDL-C \\< 100 mg/dL; for moderate risk patients, LDL-C \\< 130 mg/dL; for low-risk patients: LDL-C \\< 160 mg/dL. High-risk means coronary heart disease or risk equivalents; moderate risk means having at least 2 risk factors; low-risk means having no or 1 risk factor.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Flushing","Diarrhea","Vomiting","Headache","Nausea"]}}}